PLEASANTON, CA--(Marketwired - July 13, 2016) - ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that it received approval from the China Food and Drug Administration (CFDA) for fat layer reduction of the abdomen and flanks. Comprehensive multi-center clinical studies have validated that the CoolSculpting® procedure non-invasively reduces fat cells by an average of 20-25% in the treated area based on histological and ultrasound assessment.
"Approval from the CFDA is a significant milestone for us, as we believe the Chinese market represents tremendous opportunity given its population size and high interest in aesthetic treatments," said Mark Foley, President and Chief Executive Officer of ZELTIQ. "We are pleased to continue our global expansion strategy and introduce Chinese consumers to our proprietary CoolSculpting technology for the clinically proven, safe and effective reduction of unwanted fat."
The CoolSculpting procedure results in a noticeable and measurable reduction of fat in the treated area, and the treated fat cells are gone for good. Most patients can start to see results as soon as three weeks following treatment, with the most dramatic results occurring over a period of one to three months. Every patient is unique, so patients are encouraged to talk to their physicians about a customized treatment plan as part of the initial consultation. Additional treatments in the same or multiple areas may enhance the desired aesthetic effect.
"Our presence in the Asia-Pacific region has been growing steadily in recent years. With approval from the CFDA, we intend to expand our focus to penetrating the Chinese market and building awareness among consumers," said Todd Zavodnick, ZELTIQ's President, International. "Our goal is to establish CoolSculpting as the premier non-invasive fat reduction solution in the Chinese aesthetic market. For the remainder of 2016, we plan to conduct a controlled launch with the goal of being ready to accelerate penetration in 2017."
The CoolSculpting procedure is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
About the CoolSculpting® Procedure
The CoolSculpting procedure is a non-surgical, clinically proven procedure that selectively reduces unwanted fat using a patented cooling technology. The CoolSculpting procedure is cleared by the FDA. The CoolSculpting procedure works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed by nearly 4,000 CoolSculpting systems in over 70 countries. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure. The CoolSculpting procedure is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting system, is designed to selectively reduce unwanted fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed the CoolSculpting procedure to safely, noticeably, and measurably reduce the fat layer.
The statements made in this press release regarding ZELTIQ's belief that the Chinese Market represents a tremendous opportunity, that ZELTIQ will immediately expand its focus to penetrating the Chinese market, that ZELTIQ can establish CoolSculpting as the premier non-invasive fat reduction solution in the Chinese aesthetic market, and that ZELTIQ intends to launch the training and marketing programs that have made it a leader in the non-invasive fat reduction category globally, are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond ZELTIQ's control and that could materially affect ZELTIQ's actual business operations in the market in China. Factors that could materially affect these forward looking statements include, but are not limited to: less than anticipated demand in the market in China for ZELTIQ's CoolSculpting procedures; as well as those other risks and uncertainties set forth under the caption "Risk Factors" in ZELTIQ's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 11, 2016. These forward-looking statements speak only as of the date of this press release. ZELTIQ expressly disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.